Merck's NDA For A Pill That Combines Zetia And Lipitor Is Bounced By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Citing a need for more data, the agency refuses to file an NDA for a pill combining ezetimibe (Zetia) and atorvastatin (Pfizer's Lipitor).
You may also be interested in...
UPDATED: Zetia/Lipitor Combo’s Ongoing Clinical Equivalence Trials May Address FDA’s Data Request, Merck Says
FDA did not accept the company’s bioequivalence arguments supporting a fixed-dose combination of ezetimibe and atorvastatin. Merck believes new data that are expected to be available later this year may address the agency’s “complete response” letter.
Zetia/Lipitor Combo’s Ongoing Clinical Equivalence Trials May Address FDA’s Data Request, Merck Says
FDA did not accept the company’s bioequivalence arguments supporting a fixed-dose combination of ezetimibe and atorvastatin. Merck believes new data that are expected to be available later this year may address the agency’s “complete response” letter.
Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
The four-drug combination pill for HIV has significant sales potential, and will be a mainstay for Gilead to protect its leadership in the market, but with two novel components there is still much work to be done.